  

Login | Join | Donate | AES Connect

Search the entire site... 

ANNUAL MEETING ABSTRACTS: VIEW

« Back to Search Results

(Abst. 2.233), 2018

CANNABIDIOL TOLERANCE IN CHILDREN AND ADULTS WITH
EPILEPSY
Authors: Shimrit Uliel-Sibony, Tel-Aviv Sourasky Medical Center, Da
Hausman-Kedem, Tel-Aviv Sourasky Medical Center, Dana Children's
Aviv Sourasky Medical Center, Dana Children's Hospital

Content:

RATIONALE:
The aim of this study is to assess the tolerance rate of cannabinoids
the pediatric and adults population.

METHODS:
Prospective review of the tolerance to cannabinoids of 92 consecutiv
(mean11.8 years) with treatment-resistant epilepsy during the perio
Tolerance was defined as either the necessity to increase dose in 30
of efficacy, or response reduction of more than 30%.

RESULTS:
Ninety-two patients with treatment-resistant epilepsy of various etio
cannabis oil extract (CBD/THC ratio of 20:1) for an average of 19.8
30 (32.6%) of the patients. It was reported on an average dose of 1
time till appearance of tolerance was 7.3 months (range: 1-24 mont
58% (17 patients) showed > 50% reduction in mean monthly seizur
resist the tolerance effect, CBD dose was increased in most patients
led to achieving pervious response level in 12 and satisfying but less
15 patients. Of the patients with observed tolerance, in nine it was
tapering.

CONCLUSIONS:
Our findings suggest that cannabidiol tolerance exists and it limits th
treatment in the long-term clinical management of epilepsy in the pe

FUNDING:
No funding was received.

« Back to Search Results

About Us Press Room Contact Us Disclosure Privacy Terms & Conditions of Use

Copyright © 2020, American Epilepsy Society